Merck halted all discovery research operations in the United Kingdom and canceled plans for a £1 billion London drug research center, citing the government’s insufficient life sciences investments and unfavorable drug pricing policies. The decision reflects growing dissatisfaction within the pharmaceutical industry regarding the UK's support and reimbursement frameworks, posing challenges for innovation and investment in the country’s biotech sector.